Wednesday, July 8, 2026

biotech · Recurrent Head and Neck Cancer · Metastatic Head and Neck Cancer · PDSB

PDS Biotechnology

PDS Biotechnology is a biotech organization headquartered in Princeton, USA. It trades on NYSE under ticker PDSB. Primary therapeutic focus areas include Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer, H

Princeton, USA HQ
2005 Founded
32 Employees
Public company Type
PDSB · NYSE Ticker
Company details
Status
Public
HQ
Princeton, USA
Founded
2005
Employees
32
Programs
3
Drugs
5
Patents
11
Clinical program

U10-02-11-001

Phase 1 · mab · High-risk HPV Infection and Biopsy-proven CIN1

U10-02-11-001 for High-risk HPV Infection and Biopsy-proven CIN1 is a Phase 1 program (mab) at PDS Biotechnology Corp with 1 ClinicalTrials.gov record(s).

Internal code U10-02-11-001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
PDS Biotechnology Corp
Phase
Phase 1
Modality
mab
Indication
High-risk HPV Infection and Biopsy-proven CIN1
Status
completed
Trials
1